Table 1.
Characteristics at trial entry, exposure to magnesium sulphate and outcome at discharge from hospital for children included in follow-up and those contacted
| Children included in follow-up | Children contacted | |||
|---|---|---|---|---|
| MgSO4, n = 2254 | Placebo, n = 2229 | MgSO4, n = 1635 | Placebo, n = 1648 | |
| Mothers’ characteristics at trial entry | ||||
| Singleton pregnancy | 2094 (93) | 2096 (94) | 1522 (93) | 1554 (94) |
| Pre-eclampsia | ||||
| Severe | 526 (23) | 553 (25) | 395 (24) | 421 (26) |
| Moderate | 1047 (47) | 990 (44) | 721 (44) | 709 (43) |
| Mild | 691 (30) | 686 (31) | 519 (32) | 518 (31) |
| Prior anticonvulsant | 160 (7) | 167 (7) | 110 (7) | 110 (7) |
| ≤33 completed weeks of gestation | 529 (23) | 522 (24) | 398 (24) | 396 (24) |
| Intravenous maintenance regimen | 1429 (63) | 1391 (61) | 1142 (70) | 1118 (68) |
| High PNM country | 864 (38) | 880 (40) | 479 (29) | 515 (32) |
| Middle PNM country | 823 (37) | 786 (35) | 617 (38) | 596 (36) |
| Low PNM country | 567 (25) | 563 (25) | 539 (33) | 537 (33) |
| After trial entry | ||||
| Exposure to MgSO4 | ||||
| None | 85 (4) | 2216 (99) | 70 (4) | 1638 (99) |
| Median (IQR) (g) | 14 (5–29) | 0 | 18 (9–29) | 0 |
| Time to delivery, median (IQR) (hours) | 12 (4–42) | 11 (4–39) | 12 (4–46) | 11 (4–46) |
| Outcome at discharge from hospital | ||||
| Born ≤33 completed weeks | 435 (19) | 418 (19) | 331 (20) | 326 (20) |
| Stillbirth or died before discharge | 204 (9) | 184 (8) | 204 (12) | 184 (11) |
| In special care baby unit* | 804 (38) | 773 (37) | 576 (38) | 556 (36) |
IQR, interquartile range.
Data are n (%) unless otherwise indicated.
*
Liveborn babies only: selected children in MgSO4 group, n = 2132, and in placebo group, n = 2108; contacted children in MgSO4 group, n = 1513, and in placebo group, n = 1527.